Executive Employment AgreementExecutive Employment Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances)
ContractWarrant Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • California
THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT.
BiTE Research Collaboration AgreementBite Research Collaboration Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • New York
This BiTE Research Collaboration Agreement (“Agreement”) is made and entered into effective as of June 6, 2003 (the “Effective Date”), by and between Micromet AG, having its principal place of business at Staffelseestrasse 2, 81477, Munich, Germany (“Micromet”), and MedImmune, Inc., having its principal place of business at 35 W. Watkins Mill Road, Gaithersburg, MD 20878 (“MedImmune”). Micromet and MedImmune each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
Non-Exclusive Product License AgreementNon-Exclusive Product License Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • England and Wales
This Amendment (the “Amendment”) is made as of this 17th day of March, 2005 by and between Micromet AG, located at Staffelseestrasse 2, D-81477, Munich, Germany (“Micromet”) and Cambridge Antibody Technology Limited, located at The Milstein Building, Granta Park, Cambridgeshire CB 1 6GH, England (“CAT”) (each of Micromet, and CAT, a “Party” and, collectively, the “Parties”).
Amended and Restated Cross-License AgreementCross-License Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Cross-License Agreement (the “Agreement”) is entered into as of June 28, 2004 (the “Amendment Date”) and is hereby made effective as of April 9, 2002 (the “Effective Date”), by and between Micromet AG, having its principal offices at Staffelseestrasse 2, 81477 Munich, Germany (“Micromet”), and Enzon Pharmaceuticals, Inc., having its principal offices at 685 Route 202/206, Bridgewater, New Jersey 08807, USA (“Enzon”). Micromet and Enzon each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • New York
This Collaboration and License Agreement (the “Agreement”) is made and entered into effective as of June 6, 2003 (the “Effective Date”), by and between Micromet AG, having its principal place of business at Staffelseestrasse 2, 81477, Munich, Germany (“Micromet”), and MedImmune, Inc., having its principal place of business at 35 W. Watkins Mill Road, Gaithersburg, MD 20878 (“MedImmune”). Micromet and MedImmune each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
Research Cross-License AgreementResearch Cross-License Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • New York
provided, however, that for the purpose of this Agreement the term “Excluded Field” will not include the diagnosis, treatment and/or prevention of the above disease conditions caused by [***].
Mr. Gregor Mirow Schlossstr. 4 Rißtissen Germany Micromet, Inc. 2110 Rutherford Road Carlsbad, California 92008 Phone: (760) 494-4200 Fax: (760) 431-9980 E-mail: info@micromet-inc.com Internet: www.micromet-inc.comSeparation Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances)
This letter sets forth the substance of the separation agreement (the “Agreement”), which Micromet, Inc. (the “Company”) is offering to you to aid in your employment transition.
Non-Exclusive Product License AgreementNon-Exclusive Product License Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • England and Wales
This Amendment (the “Amendment”) is made as of this 17th day of March, 2005 by and between Micromet AG, located at Staffelseestrasse 2, D-81477, Munich, Germany (“Micromet”) and Cambridge Antibody Technology Limited, located at The Milstein Building, Granta Park, Cambridgeshire CB 1 6GH, England (“CAT”)(each of Micromet, and CAT, a “Party” and, collectively, the “Parties”).
RESEARCH AND LICENCE AGREEMENT between MICROMET AG and BIOVATION LIMITED August 14, 2001Research and License Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • England
BIOVATION LIMITED of Crombie Lodge, Aberdeen Science Park, Balgownie Drive, Aberdeen AB22 8GU, Scotland, UK (hereinafter “BIOVATION”).
GM-CSF License AgreementGm-CSF License Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • New York
This GM-CSF License Agreement (the “Agreement”) is made and entered into effective as of November 21, 2005 (the “Effective Date”), by and between Micromet AG, having its principal offices at Staffelseestrasse 2, 81477 Munich, Germany (“Micromet”), and Enzon Pharmaceuticals, Inc., having its principal offices at 685 Route 202/206, Bridgewater, New Jersey 08807, USA (“Enzon”). Micromet and Enzon each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • New York
This Collaboration and License Agreement (the “Agreement”) is made and entered into effective as of December 3, 2004 (the “Effective Date”) by and between Micromet AG, having its principal place of business at Staffelseestrasse 2, 81477, Munich, Germany (“Micromet”), and Ares Trading S.A., having its principal place of business at Zone Industrielle de l’Ouriettaz, CH-1170 Aubonne, Switzerland (“Serono”). Micromet and Serono each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
LICENSE AGREEMENTLicense Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (this “Agreement”), effective as of October 30, 2000 (the “Effective Date”), is between DYAX Corp., a Delaware corporation, having a principal place of business at One Kendall Square, Bldg. 600, Suite 623, Cambridge, Massachusetts 02139 USA (“Licensor”); and Micromet AG (“Licensee”), a corporation having a principal place of business at Am Klopfrespitz 19, D-82152 Martinsried, Germany.
Joint Venture Agreement Agreement on the Formation of a Silent Partnership by and between Technologie Beteiligungsfonds Bayern GmbH & Co. KG, Königinstraße 17, 80539 Munich - hereinafter: “Technofonds Bayern” - as represented by the sole authorized...Joint Venture Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances)
FIRST AMENDMENT TO LICENSE AGREEMENT DATED AS OF SEPTEMBER 14, 1999 by and between THE UNIVERSITY OF SOUTHERN CALIFORNIA And BIO-MANAGEMENT, INC. (NOW KNOWN AS CELL-MATRIX, INC.)License Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT (the “Amendment”) dated as of February 23, 2007 (the “Amendment Date”), is entered into by and between the University of Southern California (hereinafter “USC”), a California nonprofit corporation with its principal place of business at University Park, Los Angeles, California 90089, and Cell-Matrix, Inc., a Nevada corporation, formerly known as Bio-Management, Inc., (a wholly-owned subsidiary of Micromet, Inc., formerly known as CancerVax Corporation) (hereafter “Licensee”), having its principal place of business at 2110 Rutherford Road, Carlsbad, CA 92008, and amends the License Agreement entered into by and between Licensee and USC dated as of September 14, 1999 (the “License Agreement”). Licensee and USC are referred to in this Amendment individually as a “Party” and collectively as “Parties.”
Tarcanta, Inc. Carlsbad, CA 92008 USAEfg Vaccine License, Development, Manufacturing and Supply Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • England
This letter amends certain provisions of the EGF Agreement. Except as otherwise set forth herein, the EGF Agreement remains in full force and effect.
